الفهرس 
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 134 |  |  |
| | | from | 134 | | |
Abstract
Introduction : ince endocrine therapy can have some activity in a subset of endocrine-sensitive patients and is usually less harmful than chemotherapy, it is being investigated. Antiestrogens, aromatase inhibitors have been tested in resistant/refractory setting. The aim of work : We aimed at determining the outcome of hormonal therapy in platinum-resistant ovarian cancer in correlation to ERα and ERβ expression. Research Plan : The primary goal of this retrospective/prospective study is to evaluate the outcome of hormonal therapy (tamoxifen and AIs) in platinum-resistant ovarian cancer and its correlation to ERα and ERβ expression. Results : his study included 64 patients being resistant to platinum containing chemotherapy, Data from the electronic medical records are recovered, including baseline patient features, ER status, platinum-susceptibility status, hormone medications used, CA125 response to therapy, date of radiological progression, and date of death or last follow-up.Estrogen receptor alpha was positive in 52.60 % (10 cases) of group A cases and in 82.10 % (23 cases) of group B cases. Estrogen receptor beta was positive in 42.10 % (8 cases) of group A cases and in 55.0 % (11 cases) of group B cases. Both estrogen receptor alpha and beta were positive in 26.30 % (5 cases) of group A cases and in 50.0 % (10 cases) of group B cases. As regard hormonal treatment, all study cases received antiestrogen therapy either tamoxifen or aromatase inhibitors at event of being platinum resistant. Clinical benefit was reported starting from 3 months and was more obvious in AI group 64% versus 50% in Tamoxifen group with overall clinical benefit 59.5% and progressive disease 40% at 3 months. 38.5% of cases are still showing clinical benefit at 6 months follow up. Correlating OS with ER alpha & beta expression, it was found that longer OS with observed in both types of ER negative cases despite not achieving a statistically significant level. This may alert toward the role of GPER1 in mediating estrogen effect in ovarian carcinoma that can be modified by hormonal therapy. Anti estrogen therapy is an engaging therapy option because of its low risk of side effects. There was a low incidence of adverse events, and no fatalities were recorded. Conclusion : We recommend the use of antiestrogen therapy (Tamoxifen and Aromatase Inhibitors) for treatment of patients with platinum-resistant epithelial ovarian cancer. ERα and ERβ testing can also be used as a useful, simple, practical and reliable tool to predict the survival and therapy outcomes.